BMY
Bristol-Myers Squibb Company
- Depreciation and amortization, 2025
- $4.0B
- YoY, 2025
- −58.2%
- 5-year CAGR
- −17.3%
- 10-year CAGR
- +19.4%
Depreciation and amortization
Depreciation and amortization by fiscal year
| Period | D&A | YoY |
|---|---|---|
| 2025 | $4.0B | −58.2% |
| 2024 | $9.6B | −1.6% |
| 2023 | $9.8B | −5.0% |
| 2022 | $10.3B | −3.8% |
| 2021 | $10.7B | +2.9% |
| 2020 | $10.4B | +494.5% |
| 2019 | $1.7B | +174.1% |
| 2018 | $637M | −19.3% |
| 2017 | $789M | +26.0% |
| 2016 | $626M | −8.3% |
| 2015 | $683M | −17.6% |
| 2014 | $829M | +8.7% |
| 2013 | $763M | +12.0% |
| 2012 | $681M | +8.4% |
| 2011 | $628M | −15.6% |
| 2010 | $744M | +5.2% |
| 2009 | $707M | −13.4% |
| 2008 | $816M | −8.5% |
| 2007 | $892M | — |